GUBRA

Gubra is a biotechnology company operating through three synergistic business units: Biotech, CRO Services, and Ventures. The Biotech unit advances proprietary therapeutic programs using a disease-agnostic, AI-assisted discovery platform to optimize peptide-based drug candidates for metabolic and fibrotic diseases. The CRO Services unit delivers specialized preclinical research services to pharmaceutical and biotechnology companies worldwide, offering customized studies and advanced animal models for conditions including obesity, liver disease (MASH), kidney disease (CKD/DKD), central nervous system disorders, lung fibrosis (IPF), and diabetes. The Ventures unit incubates independent companies based on scientific research to create new drug discovery opportunities. Gubra Green is a subsidiary that allocates a portion of profits to support environmental initiatives. Founded in 2008 by Jacob Jelsing and Niels Vrang, the company serves global partners in the pharma and biotech sectors.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage gubra.dk
Sector Healthcare IR page gubra.dk/investors
Tags
preclinical research, contract research, peptide therapeutics, artificial intelligence, metabolic diseases, fibrotic diseases, drug discovery, ventures, animal models, Gubra, Gubra Biotech, Gubra CRO, Gubra Ventures, Gubra Green, GAN DIO-MASH, ReninAAV, ABBV-295, AbbVie
Press page gubra.dk/news

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 211.8%
ROI 147.5%
ROIC 187.6%
Profit margin 64.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 632.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 69
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 2.637B 265.74M 205M 199.38M 255.32M 172.3M
Net profit 1.691B -36.49M -44.52M 4.3M 67.93M 12.69M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Today, Gubra announced that its partner AbbVie presents detailed data from the 12/13-week Phase 1 study of ABBV-295 in a short oral presentation at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting in Milan, Italy.

  • ABBV-295 demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV-295 at dosing intervals beyond weekly administration, including every-other-week and monthly regimens.
  • ABBV-295 showed meaningful body weight reduction and favorable tolerability profile at all evaluated dose levels, with topline results announced earlier this year (AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog | Gubra ).
  • Results support advancement of ABBV-295, a non-incretin, amylin-based mechanism. A Phase 2 trial in adults with overweight and obesity was initiated in August 2026 (ClinicalTrials.gov ID: NCT07752979).

The detailed results being presented are from the 60 participants in Part 2B/2C of the MAD study, who were randomized to receive ABBV-295 (n = 45) or placebo (n = 15). Participants had a mean age of 41.5 years and a mean BMI of 29.3 kg/m2, and 88% were male. ABBV-295 was dose-escalated to 4, 6, or 14 mg once weekly, 14 mg every other week, or 8 mg monthly, and administered for 12 or 13 weeks. ABBV-295 is an investigational therapy that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists.

“The detailed data presented at EASD further highlight the differentiated profile of ABBV-295, including meaningful weight loss, favorable safety and tolerability, and a pharmacokinetic profile supporting the evaluation of dosing intervals beyond weekly administration. We are pleased to see the program advancing under AbbVie’s leadership,” said Markus Rohrwild, CEO of Gubra.

Key highlights from the short oral presentation include:

  • Pharmacokinetic profile supports evaluation of dosing intervals beyond weekly administration: ABBV-295 demonstrated dose-proportional increases in plasma exposure across cohorts. Median Tmax ranged from 24.0 to 48.1 hours, and the mean half-life ranged from 10.7 to 12.3 days, a profile that supported the once-weekly, every-other-week, and monthly regimens evaluated in the study.
  • Gastrointestinal (GI) safety findings: GI adverse events (AEs) were predominantly mild and occurred primarily during the first six weeks of treatment. Among participants who reported a GI AE, 92% reported mild events as the highest severity. Nausea was reported in 33.3% of participants receiving ABBV-295 compared with 20.0% receiving placebo. Diarrhea was reported in 20.0% of participants receiving ABBV-295 compared with 0.0% receiving placebo. No severe GI AEs were reported, and discontinuations due to GI AEs were infrequent overall (4.4% vs. 0.0%, all active vs. placebo).
  • Tolerability: No serious treatment-emergent adverse events (TEAEs) were reported, and most events were mild. The most commonly reported adverse events (AEs) >20% were decreased appetite, fatigue, headache, nausea, and diarrhea.
  • Meaningful weight loss observed across weekly, every-other-week, and monthly regimens: ABBV-295 demonstrated dose-dependent reductions in body weight over a 12- to 13-week treatment period. Least-squares (LS) mean body weight reductions ranged from -7.8% to -9.8% at Week 12 for the once-weekly dosing cohorts and were -9.7% for the every-other-week cohort and -7.9% for the monthly cohort at Week 13, compared with approximately -0.3% for placebo.

EASD Presentation Details:

Abstract Title Date/Time Session
Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog for the treatment of obesity Wednesday, September 30 11:45 AM–12:45 PM CEST LBA SO 07 Trials of tomorrow: new therapeutic horizons Session C

Link to today’s press release from AbbVie: AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 – Sep 30, 2026 .

About ABBV-295
ABBV-295 is an investigational, long-acting amylin analog being developed for chronic weight management and other potential indications. ABBV-295 was discovered by Gubra using Gubra’s streaMLineTM platform. ABBV-295 has not been approved by any health regulatory authority worldwide. The safety and efficacy of ABBV-295 have not been established.

About the AbbVie and Gubra partnership
In March 2025, Gubra and AbbVie entered into a license agreement for ABBV-295. Under the terms of the agreement, AbbVie will lead development and commercialization activities of ABBV-295 globally. Gubra is eligible to receive up to USD 1.875 billion in potential development, commercial, and sales-based milestone payments, as well as tiered royalties on global net sales.

Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy menstrual bleeding. HMB-003 was discovered under a collaboration between Gubra and Hemab Therapeutics, combining Gubra’s streaMLine™ peptide discovery platform with Hemab’s expertise in bleeding disorders. HMB-003 is proprietary to Hemab, and Hemab is solely responsible for its development and commercialization.

The Phase 1 study (NCT07798505) is a randomized, placebo-controlled, single-ascending-dose escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMB-003 in healthy adult volunteers.

Further details are available in Hemab Therapeutics’ press release: https://ir.hemab.com/news-releases/news-release-details/hemab-therapeutics-announces-first-participant-dosed-phase-1

About HMB-003HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor with a durable half-life – a proven therapeutic target in coagulation medicine – being developed as a novel antifibrinolytic designed to reduce bleeding across multiple settings. Engineered to directly inhibit plasmin at its active site, HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway. HMB-003 is optimized to provide sustained bleed protection across multiple high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management. For more information, please visit clinicaltrials.gov (NCT07798505).

In 2023, Gubra and Hemab Therapeutics entered into a collaboration agreement to discover a novel peptide drug candidate. The project combines Gubra’s streaMLineTM peptide discovery platform with Hemab’s expertise in in bleeding disorders. HMB-003 was discovered under this collaboration agreement. Hemab is solely responsible for development and commercialization of HMB-003.

Gubra will participate in the Morgan Stanley 24****th Annual Global Healthcare Conference in New York on September 14-16.

Markus Rohrwild, CEO of Gubra, will participate in a fireside chat on Wednesday, September 16, at 1:50 p.m. EDT (7:50 p.m. CEST).
A live audio webcast of the fireside chat will be available at:
https://event.webcasts.com/starthere.jsp?ei=1773928&tp_key=e3b909d63e&tp_special=8 . A replay of the webcast will be available at https://www.gubra.dk/investors .

Prompts

Gubra (ticker GUBRA), listed in Denmark.

ETFs Holding Gubra

ETF Weight in ETF Shares Market value As of
OZEM 2.10% 27,580 $ 1.173M Nov 17, 2026
HRTS 0.47% 4,429 $ 261.11K Aug 31, 2026